NeoGenomics Zukünftiges Wachstum
Future Kriterienprüfungen 0/6
Für NeoGenomics wird ein Gewinn- und Umsatzwachstum von 57.4% bzw. 8.5% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 56.6% pro Jahr steigen soll.
Wichtige Informationen
57.4%
Wachstumsrate der Gewinne
56.64%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 18.4% |
| Wachstumsrate der Einnahmen | 8.5% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 29 Apr 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • May 01
NEO: Expanded Test Access And Coverage Will Support Long Term Upside
Analysts have revised their fair value estimate for NeoGenomics from $17.00 to about $23.43. This change reflects updated assumptions for long term revenue growth, profit margins, and a higher future P/E multiple.
Narrativ-Update • Apr 17
NEO: Medicare Test Coverage Will Support Bullish Repricing Through 2026 Guidance
Analysts have trimmed their price target on NeoGenomics from about $14.81 to roughly $14.19, citing updated assumptions for fair value, revenue growth, profit margin and future P/E that modestly reset expectations while keeping the broader thesis intact. What's in the News PanTracer LBx received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043.
Narrativ-Update • Apr 03
NEO: Expanded Genomic Test Coverage Will Support Stronger Outlook For 2026
Analysts have raised their price target on NeoGenomics from $12.00 to $13.00, citing updated assumptions for growth, profitability, discount rate, and a higher future P/E multiple. What's in the News PanTracer LBx liquid biopsy test received coverage from the Centers for Medicare & Medicaid Services’ MolDX program under LCD L38043, expanding access for Medicare patients to blood based comprehensive genomic profiling across more than 500 genes with a seven day turnaround (Key Developments).Narrativ-Update • Mar 19
NEO: New Medicare Coverage Will Drive Bullish Repricing Through 2026 Guidance
Analysts have kept their $14.81 price target for NeoGenomics unchanged, citing stable modeled revenue growth, profit margins, and future P/E assumptions as the basis for maintaining their view. What's in the News Medicare, through the MolDX program, granted coverage for NeoGenomics' PanTracer LBx liquid biopsy test for plasma based genomic profiling in solid tumors, expanding access for Medicare patients to a blood based comprehensive genomic profiling assay that evaluates more than 500 genes with a seven day turnaround (Key Developments).Narrativ-Update • Mar 05
NEO: Legal Victory And 2025–2026 Guidance Will Drive Bullish Repricing
Analysts have raised their price target on NeoGenomics from about $14.43 to roughly $14.81, citing updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News NeoGenomics launched RaDaR ST, a circulating tumor DNA assay for molecular residual disease that uses patient specific, tumor informed panels and whole exome sequencing to track up to 48 tumor variants with an LOD95 of 11 ppm.Narrativ-Update • Feb 19
NEO: Liquid Biopsy Expansion And Legal Win Will Support Long Term Upside
Analysts have kept their $17.00 price target for NeoGenomics unchanged, reflecting only small model tweaks to the discount rate, revenue growth assumptions, profit margin expectations, and future P/E that do not materially alter their overall view of the stock. What's in the News Issued earnings guidance for 2026 with expected consolidated revenue of US$793 million to US$801 million and a projected net loss of US$63 million to US$50 million.Narrativ-Update • Feb 05
NEO: Fair Outlook Balances Leadership Transition Patent Win And Clinical Data
Narrative Update on NeoGenomics Analysts have lifted their implied fair value estimate for NeoGenomics to US$12.00 per share, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E as the key drivers behind the new price target framework. What’s in the News NeoGenomics announced a CFO succession plan, with Abhishek Jain joining as Executive Vice President on January 12, 2026 and scheduled to become CFO on March 2, 2026, as current CFO Jeff Sherman transitions toward retirement on April 14, 2026, after completing the fiscal 2025 reporting cycle.Seeking Alpha • Jan 25
NeoGenomics: Distribution Moat In Community Oncology
Summary NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO’s clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration. NEO trades at a significant discount to sector peers on EV/Sales and P/S, offering a margin of safety if execution on MRD and margin expansion materializes. Read the full article on Seeking AlphaNarrativ-Update • Jan 22
NEO: Legal Win And 2025 Guidance Will Drive Bullish Repricing
Analysts have raised their price target for NeoGenomics to about US$14.43 from roughly US$13.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that refine their view of the company’s long-term earnings power. What's in the News Issued preliminary unaudited guidance for the fourth quarter of 2025 with expected total revenue of about US$190 million and year over year growth of 11%, and full year 2025 revenue of about US$727 million with year over year growth of 10% (company guidance).Narrativ-Update • Jan 08
NEO: Future Liquid Biopsy Data Pipeline Will Support Stronger Long Term Outlook
Analysts have lifted their fair value estimate for NeoGenomics from US$14.00 to US$17.00. They cite updated assumptions around revenue growth, profit margins and future P/E that they believe better reflect the company’s outlook.Narrativ-Update • Dec 14
NEO: Upcoming Trial Readouts And Guidance Will Drive Bullish Repricing
Narrative Update on NeoGenomics Analysts have modestly raised their price target on NeoGenomics to approximately 13.44 dollars from about 13.17 dollars, citing slightly stronger long term revenue growth expectations and a marginally higher future earnings multiple, despite a nearly unchanged discount rate and profit margin outlook. What's in the News Upcoming SABCS 2025 presentations will showcase RaDaR 1.0 ctDNA data from the SURVIVE HERoes Phase III trial and CLEVER study in early breast cancer, supporting ctDNA guided surveillance and earlier intervention strategies (company announcement).Narrativ-Update • Nov 29
NEO: Upcoming Research and Earnings Guidance Will Shape Market Expectations
Analysts have slightly raised their price target for NeoGenomics from $13.06 to $13.17 per share. This reflects updated assessments of future profitability and market growth potential.Narrativ-Update • Nov 15
NEO: Upcoming Research Presentations Are Expected To Drive Solid Tumor Detection Momentum
Analysts have raised their fair value estimate for NeoGenomics from $11.72 to $13.06. This change is attributed to slightly improved revenue growth projections, as well as a modest increase in profit margins and future valuation multiples.Narrativ-Update • Nov 01
NEO: Upcoming Research Presentations Will Accelerate Future Oncology Diagnostic Opportunities
Analysts have raised their price target for NeoGenomics from $10.44 to $11.72 per share. They cite marginal improvements in projected revenue growth and profit margin estimates.Narrativ-Update • Oct 18
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
Analysts have raised their price target for NeoGenomics from $9.78 to $10.44 per share, citing slightly improved revenue growth projections and a modestly higher future price-to-earnings multiple. What's in the News NeoGenomics announced the presentation of key MRD assay data, including results from interventional therapy trials, at the upcoming ESMO Congress 2025 in Berlin.Narrativ-Update • Aug 30
Advanced Oncology Diagnostics And NGS Capabilities Will Create Future Opportunities
The higher analyst price target for NeoGenomics reflects an expansion in its future P/E multiple despite stable revenue growth forecasts, resulting in a revised fair value of $9.78. What's in the News U.S. District Court invalidated certain Natera patents asserted against NeoGenomics’ RaDaR v1.1 test, but the decision does not affect the '035 patent that previously led to a permanent injunction on RaDaR v1.0. NeoGenomics launched NEO PanTracer LBx, a blood-based comprehensive genomic profiling (CGP) test targeting the expanding liquid biopsy market and enhancing its pan-solid tumor CGP portfolio.Analyseartikel • Aug 27
Would NeoGenomics (NASDAQ:NEO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jul 30
Market Cool On NeoGenomics, Inc.'s (NASDAQ:NEO) Revenues Pushing Shares 27% Lower
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • May 23
Take Care Before Jumping Onto NeoGenomics, Inc. (NASDAQ:NEO) Even Though It's 25% Cheaper
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 25% in the last thirty...
Neues Narrativ • Mar 23
PanTracer Launch And MRD Collaboration Will Strengthen Future Cancer Testing Leadership
NeoGenomics' strategic investments and collaborations are expected to enhance customer experiences, boost test volumes, and strengthen competitive positioning in MRD monitoring and Heme testing.Analyseartikel • Mar 08
NeoGenomics, Inc.'s (NASDAQ:NEO) Stock Retreats 28% But Revenues Haven't Escaped The Attention Of Investors
Unfortunately for some shareholders, the NeoGenomics, Inc. ( NASDAQ:NEO ) share price has dived 28% in the last thirty...Seeking Alpha • Feb 28
NeoGenomics: Decent Fundamentals, But Still Overvalued
Summary NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitability is a concern. Intrinsic value calculations using the Graham's Formula and DCF model suggest the stock may not yet be done falling. I am recommending caution. Read the full article on Seeking AlphaAnalyseartikel • Feb 18
Here's Why NeoGenomics (NASDAQ:NEO) Can Afford Some Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Jan 14
What You Can Learn From NeoGenomics, Inc.'s (NASDAQ:NEO) P/S After Its 29% Share Price Crash
NeoGenomics, Inc. ( NASDAQ:NEO ) shares have had a horrible month, losing 29% after a relatively good period...Analyseartikel • Nov 23
NeoGenomics, Inc. (NASDAQ:NEO) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders are no doubt pleased to see that the share price has bounced 25% in the...Analyseartikel • Oct 16
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Aug 01
Investors Appear Satisfied With NeoGenomics, Inc.'s (NASDAQ:NEO) Prospects As Shares Rocket 29%
NeoGenomics, Inc. ( NASDAQ:NEO ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • Jul 15
Is NeoGenomics (NASDAQ:NEO) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 965 | -21 | N/A | N/A | 6 |
| 12/31/2027 | 881 | -37 | N/A | 74 | 12 |
| 12/31/2026 | 800 | -58 | N/A | 39 | 12 |
| 3/31/2026 | 746 | -99 | -5 | 22 | N/A |
| 12/31/2025 | 727 | -108 | -22 | 5 | N/A |
| 9/30/2025 | 709 | -113 | -17 | 14 | N/A |
| 6/30/2025 | 689 | -104 | -19 | 14 | N/A |
| 3/31/2025 | 672 | -78 | -32 | 8 | N/A |
| 12/31/2024 | 661 | -79 | -34 | 7 | N/A |
| 9/30/2024 | 644 | -78 | -22 | 15 | N/A |
| 6/30/2024 | 628 | -79 | -30 | 0 | N/A |
| 3/31/2024 | 611 | -84 | -40 | -15 | N/A |
| 12/31/2023 | 592 | -88 | -31 | -2 | N/A |
| 9/30/2023 | 575 | -96 | -50 | -23 | N/A |
| 6/30/2023 | 552 | -115 | -64 | -34 | N/A |
| 3/31/2023 | 530 | -126 | -82 | -50 | N/A |
| 12/31/2022 | 510 | -144 | -97 | -66 | N/A |
| 9/30/2022 | 497 | -163 | -120 | -82 | N/A |
| 6/30/2022 | 489 | -147 | -119 | -74 | N/A |
| 3/31/2022 | 486 | -36 | -115 | -58 | N/A |
| 12/31/2021 | 484 | -8 | -91 | -27 | N/A |
| 9/30/2021 | 485 | 49 | -65 | -1 | N/A |
| 6/30/2021 | 489 | 72 | -49 | 7 | N/A |
| 3/31/2021 | 454 | -11 | -30 | 11 | N/A |
| 12/31/2020 | 444 | 4 | -28 | 1 | N/A |
| 9/30/2020 | 425 | -5 | -25 | -1 | N/A |
| 6/30/2020 | 405 | -5 | -6 | 17 | N/A |
| 3/31/2020 | 419 | 3 | -11 | 10 | N/A |
| 12/31/2019 | 409 | 8 | N/A | 23 | N/A |
| 9/30/2019 | 378 | 2 | N/A | 35 | N/A |
| 6/30/2019 | 343 | 2 | N/A | 25 | N/A |
| 3/31/2019 | 309 | 6 | N/A | 37 | N/A |
| 12/31/2018 | 277 | 6 | N/A | 45 | N/A |
| 9/30/2018 | 262 | 8 | N/A | 35 | N/A |
| 6/30/2018 | 252 | -1 | N/A | 34 | N/A |
| 3/31/2018 | 246 | -9 | N/A | 34 | N/A |
| 12/31/2017 | 240 | -11 | N/A | 18 | N/A |
| 9/30/2017 | 239 | -27 | N/A | 12 | N/A |
| 6/30/2017 | 241 | -26 | N/A | 14 | N/A |
| 3/31/2017 | 242 | -29 | N/A | 13 | N/A |
| 12/31/2016 | 232 | -31 | N/A | 21 | N/A |
| 9/30/2016 | 211 | -18 | N/A | 24 | N/A |
| 6/30/2016 | 175 | -12 | N/A | 17 | N/A |
| 3/31/2016 | 136 | -7 | N/A | 14 | N/A |
| 12/31/2015 | 100 | -3 | N/A | 6 | N/A |
| 9/30/2015 | 98 | 0 | N/A | 5 | N/A |
| 6/30/2015 | 96 | 0 | N/A | 6 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: NEO wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: NEODie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (11.7% pro Jahr).
Hohe Wachstumseinnahmen: NEODie Einnahmen des Unternehmens (8.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von NEO in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 04:11 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
NeoGenomics, Inc. wird von 25 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Bruce Jackson | Benchmark Company |
| Raymond Myers | Benchmark Company |
| Michael Ryskin | BofA Global Research |